Psoriatic Arthritis

Subscribe to Selected New Research on Psoriatic Arthritis

1221 relevant articles (111 outcomes, 190 trials/studies) found for this Disease

Description: Syndrome in which psoriasis is associated with arthritis, often involving inflammation in terminal interphalangeal joints. A rheumatoid factor is not usually present in the sera of affected individuals.

Also Known As:

Arthritis, Psoriatic; Arthritic Psoriasis; Psoriasis Arthropathica; Psoriasis, Arthritic

Relationship Network

Disease Context: Research Results

Musculoskeletal Diseases: 83

Bone Diseases: 2380

Spinal Diseases: 110

Spondylarthritis: 147

Spondylarthropathies: 216

Psoriatic Arthritis: 1221

Joint Diseases: 1502

Arthritis: 14194

Psoriatic Arthritis: 1221

Spondylarthritis: 147

Spondylarthropathies: 216

Psoriatic Arthritis: 1221

Skin and Connective Tissue Diseases

Skin Diseases: 5943

Papulosquamous Skin Diseases: 6

Psoriasis: 10262

Psoriatic Arthritis: 1221

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris)
2.	Ankylosing Spondylitis
3.	Rheumatoid Arthritis
4.	Arthritis (Polyarthritis)
5.	Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)

Experts

1.	Mease, Philip J: 9 articles (05/2007 - 04/2002)
2.	Gladman, Dafna: 8 articles (07/2008 - 09/2002)
3.	Gladman, D D: 8 articles (08/2007 - 06/2001)
4.	Gladman, Dafna D: 7 articles (10/2008 - 10/2005)
5.	Antoni, C: 7 articles (08/2007 - 03/2001)
6.	Ritchlin, Christopher T: 6 articles (08/2008 - 02/2003)
7.	Spadaro, A: 5 articles (07/2008 - 02/2002)
8.	Rahman, Proton: 5 articles (07/2008 - 07/2006)
9.	de Vlam, K: 5 articles (01/2008 - 08/2005)
10.	Beutler, A: 5 articles (08/2007 - 08/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Psoriatic Arthritis:

1.	TNFR-Fc fusion protein (etanercept)FDA Link 01/01/2003 - "In the 24-week study, ACR20 response rates (50 vs 13%), psoriatic arthritis response rates (70 vs 23%) and the median improvement in skin lesions (33 vs 0%) were significantly greater in etanercept than in placebo recipients" 01/01/2003 - "In patients with psoriatic arthritis, etanercept 25mg twice weekly significantly reduced disease activity and improved skin lesions in two double-blind, placebo-controlled, 12- to 24-week trials" 01/01/2002 - "In the 24-week study, ACR20 response rates (50 vs 13%), psoriatic arthritis response rates (70 vs 23%) and the median improvement in skin lesions (33 vs 0%) were significantly greater in etanercept than in placebo recipients" 01/01/2002 - "In patients with psoriatic arthritis, etanercept 25mg twice weekly significantly reduced disease activity and improved skin lesions in two double-blind, placebo-controlled, 12- to 24-week trials" 11/01/2000 - "In patients with severe psoriatic arthritis (PsA), a double blind, placebo controlled study demonstrated that etanercept was also effective in reducing disease activity in PsA" Order ALL the reference details at left...
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/01/2008 - "All 3 TNF-alpha inhibitors were significantly more effective than placebo on the basis of Psoriatic Arthritis Response Criteria (PsARC) and American College of Rheumatology response criteria ACR20, ACR50, and ACR70 ratings" 05/01/2008 - "Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials." 03/01/2007 - "Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study." 08/01/2005 - "This paper examines the most recent data from therapeutic trials in psoriatic arthritis, with particular emphasis on the effectiveness of the tumor necrosis factor inhibitors" 09/01/2008 - "TNF-alpha antagonists can regulate differentiation and activation of osteoclasts, thus reducing bone destruction in psoriatic arthritis" Order ALL the reference details at left...
3.	infliximab (Remicade)FDA Link 08/01/2006 - "OBJECTIVE: Infliximab is effective in improving signs and symptoms of joint/skin involvement, functional status, and quality of life in patients with psoriatic arthritis (PsA)" 08/01/2005 - "OBJECTIVES: To evaluate further in a phase III, double blind trial the efficacy of infliximab in patients with active psoriatic arthritis (PsA), as observed in the smaller IMPACT trial" 06/01/2007 - "Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis." 08/15/2003 - "Efficacy of infliximab in resistant psoriatic arthritis." 05/01/2008 - "Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)." Order ALL the reference details at left...
4.	adalimumab (Humira)FDA Link 02/01/2007 - "Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial." 02/01/2007 - "Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial." 10/01/2005 - "Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial." 06/01/2008 - "Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab." 12/01/2007 - "Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis." Order ALL the reference details at left...
5.	Methotrexate (Mexate)FDA LinkGeneric 11/01/1994 - "Methotrexate can be used early in the course of psoriatic arthritis with good results." 12/01/1995 - "Is methotrexate really effective in patients with psoriatic arthritis?" 07/01/2008 - "The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate." 03/01/2008 - "OBJECTIVE: In a previous study in our clinic, methotrexate (MTX) conferred no advantage with respect to clinical response or progression of damage after 24 months in patients with psoriatic arthritis (PsA)" 08/01/2007 - "The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study." Order ALL the reference details at left...
6.	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/01/2000 - "An open 18-week study with a preparation of cyclosporin administered to patients with psoriatic arthritis confirmed the therapeutic efficacy of the preparation" 01/01/1993 - "Therapeutic efficacy of oral low-dose cyclosporin A in severe psoriatic arthritis." 08/01/1990 - "Eight patients with psoriatic arthritis entered an open study to determine the efficacy of oral cyclosporin A for their treatment" 04/01/1989 - "The short-term efficacy of cyclosporine in the treatment of six patients with moderately severe to severe psoriatic arthritis was evaluated in an open study" 04/01/2002 - "Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis." Order ALL the reference details at left...
7.	Sulfasalazine (Azulfidine)FDA LinkGeneric 09/01/1991 - "Sulfasalazine appears to be an effective second line agent for the treatment of psoriatic arthritis" 10/01/1998 - "METHODS: Patients who were given sulfasalazine during their attendance at the University of Toronto Psoriatic Arthritis Clinic were enrolled in the study" 07/01/1996 - "A prospective double-blind, placebo-controlled, randomized study of 24 weeks duration was carried out comparing the efficacy and tolerability of sulphasalazine (SSZ) versus placebo in patients with psoriatic arthritis" 07/01/1996 - "Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study." 05/01/1995 - "Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial." Order ALL the reference details at left...
8.	Antirheumatic Agents (DMARD)IBA 07/01/2004 - "A new crop of biologics and pharmaceuticals with increased molecular specificity compared with traditional immunosuppressant disease-modifying antirheumatic drugs have been shown to be highly effective in inhibiting the symptoms and progression of psoriatic arthritis with less severe side effects" 05/01/2002 - "Few prospective placebo-controlled studies have evaluated disease-modifying antirheumatic drugs (DMARDs) in the treatment of peripheral psoriatic arthritis" 06/01/1996 - "Our aim is to study the termination of disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA) and the causes of withdrawal" 06/01/2008 - "A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis." 05/01/2002 - "Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis." Order ALL the reference details at left...
9.	Bromocriptine (Parlodel)FDA LinkGeneric 10/01/1995 - "Therapeutic efficacy of bromocriptine in psoriatic arthritis (two case-reports)" 02/01/1987 - "Treatment of psoriatic arthritis with bromocriptine." 10/15/1986 - "35 patients suffering from psoriatic arthritis were systemically treated with bromocriptine at increasing doses, starting at 2.5 mg up to 30 mg per day" 10/15/1986 - "Treatment of psoriasis arthropathica with bromocriptine]" 04/01/1994 - "High PRL levels have been found in Reiter's syndrome patients and bromocriptine treatment has been reported effective in these patients and psoriatic arthritis patients" Order ALL the reference details at left...
10.	Colchicine FDA Link 08/01/1987 - "We investigated the use of colchicine in psoriatic arthritis to determine if we could confirm the good results obtained in an earlier, uncontrolled study" 11/01/1993 - "OBJECTIVE--To test the hypothesis that colchicine is an effective treatment of psoriatic arthritis" 08/01/1987 - "Our results indicate that 1.5 mg colchicine daily is an effective treatment for psoriatic arthritis." 11/01/1993 - "CONCLUSIONS--In conclusion, our study did not provide evidence that colchicine is of therapeutic value in the treatment of psoriatic arthritis." 11/01/1993 - "METHODS--Twenty five patients with psoriatic arthritis were entered into a two centre, double blind, crossover study of 23 weeks' duration comparing the therapeutic effect of colchicine (0.6-1.8 mg/day) with placebo" Order ALL the reference details at left...

Therapies and Procedures

1.	Biological Therapy 10/15/2006 - "OBJECTIVE: The aim of the study was to present the epidemiology and progression of psoriatic arthritis in Hungary based on national and international data, to assess the target population for biological therapy and to analyze their effectiveness, reviewing the available literature of randomized controlled trials" 03/01/2005 - "Recent studies with biological therapy in psoriatic arthritis (PsA) have highlighted the need for validated and widely accepted assessment tools and outcome measures for this disease" 01/01/2007 - "Biologic therapy of psoriatic arthritis." 11/01/2005 - "Recent advances in biologic therapies have provided hope for patients with psoriatic arthritis (PsA)" 08/01/2003 - "Evaluation and management of psoriatic arthritis: the role of biologic therapy." Order ALL the reference details at left...
2.	Drug Therapy (Chemotherapy) 10/01/2003 - "METHODS: We reviewed MedLine up to November 2002, searching for 'psoriatic arthritis', 'drug therapy, 'controlled trials' and 'outcomes' and all possible acronyms for these terms" 07/01/2004 - "The goal of modern treatment is to target such immune responses that lead to the formation of psoriatic plaques and psoriatic arthritis using selective immunomodulating pharmacotherapy" 11/01/2002 - "Disease-modifying antirheumatic drug therapy for psoriatic arthritis." 05/01/1995 - "Psoriatic arthritis (PsA) is often poorly responsive to 2nd line antirheumatic drug therapy" 04/01/1983 - "Pharmacotherapy of psoriatic arthritis]" Order ALL the reference details at left...
3.	Baths 05/01/1999 - "A trial of dry air effervescent baths and low-temperature peloid applications was made in 109 patients with psoriatic arthritis (PA)" 01/01/1998 - "Low-temperature peloids and dry effervescent baths were tried in the treatment of 106 patients with psoriatic arthritis" 11/01/1987 - "Therapeutic efficacy of dry-air radon baths in the rehabilitation of patients with psoriatic arthritis]" 03/01/2003 - "Efficacy of radon baths of different concentration in psoriatic arthritis]" 05/01/1999 - "The effect of carbon dioxide baths and applications of low-temperature peloids on the immune function of patients with psoriatic arthritis]" Order ALL the reference details at left...
4.	Balneology 01/01/2000 - "The purpose of this study was to evaluate the immediate and delayed effects of balneotherapy at the Dead Sea on patients with psoriatic arthritis (PsA)" 01/01/1984 - "Balneotherapy and heliomarinotherapy in the treatment and rehabilitation of patients with psoriatic arthritis]" 02/01/2001 - "CONCLUSIONS: Balneotherapy at the Dead Sea area appears to produce a statistically significant substantial improvement in the number of active joints and tender points in both male and female patients with fibromyalgia and psoriatic arthritis" 02/01/2001 - "METHODS: Twenty-eight patients with psoriatic arthritis and fibromyalgia were treated with various modalities of balneotherapy at the Dead Sea area" 02/01/2001 - "OBJECTIVES: To assess the effectiveness of balneotherapy at the Dead Sea area in the treatment of patients suffering from both fibromyalgia and psoriatic arthritis" Order ALL the reference details at left...
5.	Therapeutics 07/01/2004 - "OBJECTIVE: Therapeutics used to treat inflammatory diseases, including psoriatic arthritis (PsA), may potentially interfere with normal immune system function" 03/01/2005 - "As a result of progress in immunology and biotechnology, several potent novel therapeutics have recently emerged for the treatment of patients with various immunologically driven systemic inflammatory conditions, including psoriasis and psoriatic arthritis" 07/01/2002 - "Anti-TNF- alpha -directed therapeutics have been shown to be dramatically effective in short-term (12 week) placebo-controlled trials in both ankylosing spondylitis and psoriatic arthritis whilst observational cohorts describe efficacy that is maintained for over one year" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Psoriatic Arthritis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 111 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>